Zastrow Stefan, Brookman-May Sabine, Cong Thi Anh Phuong, Jurk Stanislaw, von Bar Immanuel, Novotny Vladimir, Wirth Manfred
Department of Urology, TU Dresden, University Hospital Carl Gustav Carus, Fetscherstrasse 74, 01307, Dresden, Germany,
World J Urol. 2015 Mar;33(3):381-8. doi: 10.1007/s00345-014-1321-6. Epub 2014 May 22.
To predict outcome of patients with renal cell carcinoma (RCC) who undergo surgical therapy, risk models and nomograms are valuable tools. External validation on independent datasets is crucial for evaluating accuracy and generalizability of these models. The objective of the present study was to externally validate the postoperative nomogram developed by Karakiewicz et al. for prediction of cancer-specific survival.
A total of 1,480 consecutive patients with a median follow-up of 82 months (IQR 46-128) were included into this analysis with 268 RCC-specific deaths. Nomogram-estimated survival probabilities were compared with survival probabilities of the actual cohort, and concordance indices were calculated. Calibration plots and decision curve analyses were used for evaluating calibration and clinical net benefit of the nomogram.
Concordance between predictions of the nomogram and survival rates of the cohort was 0.911 after 12, 0.909 after 24 months and 0.896 after 60 months. Comparison of predicted probabilities and actual survival estimates with calibration plots showed an overestimation of tumor-specific survival based on nomogram predictions of high-risk patients, although calibration plots showed a reasonable calibration for probability ranges of interest. Decision curve analysis showed a positive net benefit of nomogram predictions for our patient cohort.
The postoperative Karakiewicz nomogram provides a good concordance in this external cohort and is reasonably calibrated. It may overestimate tumor-specific survival in high-risk patients, which should be kept in mind when counseling patients. A positive net benefit of nomogram predictions was proven.
对于接受手术治疗的肾细胞癌(RCC)患者,风险模型和列线图是预测预后的重要工具。在独立数据集上进行外部验证对于评估这些模型的准确性和通用性至关重要。本研究的目的是对Karakiewicz等人开发的用于预测癌症特异性生存的术后列线图进行外部验证。
本分析纳入了1480例连续患者,中位随访时间为82个月(四分位间距46 - 128个月),其中有268例RCC特异性死亡。将列线图估计的生存概率与实际队列的生存概率进行比较,并计算一致性指数。使用校准图和决策曲线分析来评估列线图的校准情况和临床净效益。
列线图预测与队列生存率之间的一致性在12个月时为0.911,24个月时为0.909,60个月时为0.896。通过校准图比较预测概率和实际生存估计值发现,基于列线图对高危患者的预测,肿瘤特异性生存存在高估,不过校准图在感兴趣的概率范围内显示出合理的校准。决策曲线分析表明列线图预测对我们的患者队列具有正净效益。
术后Karakiewicz列线图在这个外部队列中具有良好的一致性且校准合理。它可能高估高危患者的肿瘤特异性生存,在为患者提供咨询时应牢记这一点。已证明列线图预测具有正净效益。